This page was translated automatically from Turkish. Read the original

This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it.

EV1125

Systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression

SYSTEMIC INFLAMMATION AND RESPONSE TO ANTI-INFLAMMATORY INTERVENTIONS IN TREATMENT-RESISTANT DEPRESSION

Response to anti-inflammatory interventions is primarily observed in patients with elevated inflammatory markers at baseline, suggesting the existence of biological subgroups in treatment-resistant depression.

The aim of this study was to synthesize clinical evidence on the relationship between systemic inflammation and response to anti-inflammatory interventions in treatment-resistant depression (TRD). PubMed, Embase, and PsycINFO were searched through January 2025; randomized controlled trials (RCTs) and meta-analyses evaluating anti-inflammatory interventions in adults with TRD were included, while observational studies, preclinical research, and case reports were excluded. Outcome measures included antidepressant response, remission, and associations with systemic inflammatory markers, and ten studies met the predefined eligibility criteria. COX-2 inhibitors such as celecoxib produced significant symptom reductions in multiple studies, with reported effect sizes ranging from 0.4 to 0.6. Immunomodulators such as minocycline showed moderate benefits, particularly for motivational symptoms. Therapeutic response was consistently associated with elevated baseline levels of C-reactive protein (CRP) and pro-inflammatory cytokines, with less benefit observed in patients without inflammatory activation. The authors conclude that anti-inflammatory strategies are a promising adjunctive approach for patients with elevated inflammatory markers, while further studies are needed to establish standardized patient selection criteria and evaluate long-term safety.

All WCP 2026 summaries